



SMS Lifesciences India Limited

Registered & Corporate Office :

Plot No. 19-III, Road No. 71,
Opp. Bharatiya Vidya Bhavan Public School,
Jubilee Hills, Hyderabad - 500 096, Telangana, INDIA.
Tel : +91-040-6628 8888, Fax : +91-40-2355 1401
CIN : L74930TG2006PLC050223
Email : info@smslife.in, Website : www.smslife.in

June 9, 2022

To

BSE Limited,

Listing Department, P J Towers,
Dalal Street,
Mumbai – 400 001.

Scrip Code: 540679

Through: BSE Listing Center

National Stock Exchange of India Limited,

Listing Department, "Exchange Plaza",
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Trading Symbol: SMSLIFE

Through: NSE Digital Portal

SUB: DISCLOSURE OF RELATED PARTY TRANSACTIONS ON CONSOLIDATED BASIS [H2-F22].

Ref: Regulation 23 (9) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to the above-cited subject, we are submitting the disclosures of Related Party Transactions, for the half year ended on March 31, 2022, on a consolidated basis in the format specified under SEBI Circular no. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021.

The audited financial results were approved by the Board of Directors on May 28, 2022.

Kindly take the same on record and suitably disseminated it to all concerned.

For SMS Lifesciences India Limited


Trupri Ranjan Mohanty
Company Secretary



[Enclosed: a/a]

Consolidated Related Party Disclosure for the half year ended March 31, 2022

[Reg. 23 (9) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015]

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These

S.No	Details of the Party (listed entity / subsidiary) entering in to the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee (Ref - Note 1)	Value of transaction during reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or			Details of the loans, inter-corporate deposits, advances or investments				purpose for which the funds will be utilised by the ultimate recipient of funds (end-use)																													
	Name	PAN (Ref - Note 2)	Name	PAN (Ref - Note 2)	Relationship of the counter party with the listed entity or its subsidiary				Opening Balance	Closing Balance	Nature of indebtedness	Cost	Tenure	Nature (loans/advance/inter-corporate deposit/investment)	Interest rate (%)	Tenure	Secured/Unsecured																														
1	SMS Lifesciences India Limited		R-Chem (Somanahalli) Pvt Ltd	-	Enterprises over which Directors or their relatives exercise significant influence	Purchases	500.00	266.43	-	-	-	-	-	-	-	-	-	-																													
2						Sales	800.00	89.53	-	-	-	-	-	-	-	-	-	-	-	-	-																										
3						Conversion Charges paid	2,000.00	863.46	392.72	118.36	-	-	-	-	-	-	-	-	-	-	-																										
4			Mahi Drugs Pvt Ltd	-	Wholly Owned Subsidiary (Ref - Note 3)	Enterprises over which Directors or their relatives exercise significant influence	Purchases	3,000.00	1,905.56	3,144.66	1,760.76	-	-	-	-	-	-	-	-	-																											
5							Sales	1,500.00	446.12	-	-	-	-	-	-	-	-	-	-	-	-	-																									
6			SMS Pharmaceuticals Ltd	-	Enterprises over which Directors or their relatives exercise significant influence	-	Key Management Personnel	Sales	5,000.00	140.13	86.97	46.02	-	-	-	-	-	-	-	-																											
7								TVVSN Murthy	-	Key Management Personnel	Remuneration	100.37	100.37	7.22	7.23	-	-	-	-	-	-	-	-	-																							
8											Loan Taken	-	-	495.00	495.00	-	-	-	Loan	9.50%	As mutually agreed	Unsecured	Business purpose																								
9											Interest on Loan	19.22	19.22	10.67	10.44	-	-	-	-	-	-	-	-	-	-																						
10								N Rajendra Prasad	-	Key Management Personnel	-	Key Management Personnel	Remuneration	9.08	9.08	1.19	1.07	-	-	-	-	-	-	-	-																						
11													Trupti Banjan Mohanty	-	Key Management Personnel	-	Key Management Personnel	Remuneration	4.50	4.50	0.64	0.59	-	-	-	-	-	-	-																		
12																		T V Praveen	-	Executive Director	-	Executive Director	Remuneration	36.00	36.00	3.52	3.52	-	-	-	-	-	-	-													
13																							G Sudeepthi	-	Whole Time Director	-	Whole Time Director	Remuneration	14.00	11.25	1.03	1.24	-	-	-	-	-	-	-								
14																												P Sarath Kumar	-	Independent Director	-	Independent Director	Sitting Fee	-	3.30	-	-	-	-	-	-	-	-				
15																																	P Venkata Subbarao	-	Independent Director	-	Independent Director	Sitting Fee	-	2.30	-	-	-	-	-	-	-
16			K Shravan	-	Independent Director	-	Independent Director																															Sitting Fee	-	1.15	-	-	-	-	-	-	-
17																																						Mannam Malakondaiah	-	Independent Director	-	Independent Director	Sitting Fee	-	2.15	-	-
18			Srinivasa Samavedam	-	Independent Director	-	Independent Director	Sitting Fee	-	1.30	-	-	-	-	-	-	-	-																													
19	Mahi Drugs Private Limited							R-Chem (Somanahalli) Pvt Ltd	-	Enterprises over which Directors or their relatives exercise significant influence	Purchases	30.00	3.94	-	-	-	-	-	-	-	-	-																									
20			Sales	50.00	43.23	-24.53	14.76				-	-	-	-	-	-	-	-	-																												
21			G Venkata Chaitanaya	-	Relative of Key Management Personnel	Remuneration	5.77				5.77	1.40	-	-	-	-	-	-	-	-	-																										

Note:

- The value of the related party transactions denotes the amount approved by the Audit Committee/ Board of Directors of SMS Lifesciences India Limited for year 2021-22, subject to approval of shareholders, wherever applicable.
- As per the guidance note for disclosure of related party transactions dated April 25, 2022, issued by the Stock Exchanges, since the Company is filing the RPT disclosure in PDF format, the PAN details are not to be included in the disclosure.
- Ceased as "Wholly Owned Subsidiary" w.e.f. February 7, 2022, but continue as Subsidiary.

